{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:54:26Z","timestamp":1791942866801,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011699","name":"BRACE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jmb.2020.11.005","type":"journal-article","created":{"date-parts":[[2020,11,10]],"date-time":"2020-11-10T21:32:58Z","timestamp":1605043978000},"page":"166706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Library Derived 4554W Peptide Inhibits Primary Nucleation of \u03b1-Synuclein"],"prefix":"10.1016","volume":"432","author":[{"given":"Richard M.","family":"Meade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.C.","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody M.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2020.11.005_b0005","first-page":"367","article-title":"Abnormal accumulation of NACP\/alpha-synuclein in neurodegenerative disorders","volume":"152","author":"Takeda","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jmb.2020.11.005_b0010","first-page":"S53","article-title":"The synucleinopathies: twenty years on","volume":"7","author":"Goedert","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jmb.2020.11.005_b0015","first-page":"10","article-title":"Cryo-EM of full-length alpha-synuclein reveals fibril polymorphs with a common structural kernel","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jmb.2020.11.005_b0020","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson's disease \u2013 lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jmb.2020.11.005_b0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1021\/acschembio.9b00312","article-title":"Probing the origin of the toxicity of oligomeric aggregates of alpha-synuclein with antibodies","volume":"14","author":"Cascella","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jmb.2020.11.005_b0030","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1021\/ja411577t","article-title":"The role of stable alpha-synuclein oligomers in the molecular events underlying amyloid formation","volume":"136","author":"Lorenzen","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jmb.2020.11.005_b0035","first-page":"E1994","article-title":"Structural characterization of toxic oligomers that are kinetically trapped during alpha-synuclein fibril formation","volume":"112","author":"Chen","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jmb.2020.11.005_b0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/srep24526","article-title":"Structural and functional properties of prefibrillar alpha-synuclein oligomers","volume":"6","author":"Pieri","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2020.11.005_b0045","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.aan6160","article-title":"Structural basis of membrane disruption and cellular toxicity by alpha-synuclein oligomers","volume":"358","author":"Fusco","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jmb.2020.11.005_b0050","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.drudis.2018.10.002","article-title":"Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects","volume":"24","author":"Rastogi","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jmb.2020.11.005_b0055","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4155\/fmc.10.259","article-title":"Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention","volume":"2","author":"Mason","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jmb.2020.11.005_b0060","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.jmb.2020.11.005_b0065","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.4155\/fmc.15.139","article-title":"Toward peptide-based inhibitors as therapies for Parkinson's disease","volume":"7","author":"Mason","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jmb.2020.11.005_b0070","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1074\/jbc.M114.620484","article-title":"Intracellular screening of a peptide library to derive a potent peptide inhibitor of alpha-synuclein aggregation","volume":"290","author":"Cheruvara","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2020.11.005_b0075","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nchembio.1750","article-title":"Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation","volume":"11","author":"Galvagnion","year":"2015","journal-title":"Nature Chem. Biol."},{"key":"10.1016\/j.jmb.2020.11.005_b0080","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jmb.2020.11.005_b0085","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","article-title":"Multistep inhibition of alpha-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine","volume":"13","author":"Perni","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jmb.2020.11.005_b0090","doi-asserted-by":"crossref","first-page":"36010","DOI":"10.1038\/srep36010","article-title":"beta-Synuclein suppresses both the initiation and amplification steps of alpha-synuclein aggregation via competitive binding to surfaces","volume":"6","author":"Brown","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2020.11.005_b0095","doi-asserted-by":"crossref","first-page":"7671","DOI":"10.1073\/pnas.1315346111","article-title":"Solution conditions determine the relative importance of nucleation and growth processes in alpha-synuclein aggregation","volume":"111","author":"Buell","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jmb.2020.11.005_b0100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7554\/eLife.46112","article-title":"An engineered monomer binding-protein for alpha-synuclein efficiently inhibits the proliferation of amyloid fibrils","volume":"8","author":"Agerschou","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.jmb.2020.11.005_b0105","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1038\/s41467-020-16386-3","article-title":"Parkinson's disease associated mutation E46K of alpha-synuclein triggers the formation of a distinct fibril structure","volume":"11","author":"Zhao","year":"2020","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2020.11.005_b0110","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/10897","article-title":"An in vivo library-versus-library selection of optimized protein-protein interactions","volume":"17","author":"Pelletier","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jmb.2020.11.005_b0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/protein\/gzt021","article-title":"Combining intracellular selection with protein-fragment complementation to derive A\u03b2 interacting peptides","volume":"26","author":"Acerra","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.jmb.2020.11.005_b0120","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/pro.2509","article-title":"Intracellular selection of peptide inhibitors that target disulphide-bridged Abeta42 oligomers","volume":"23","author":"Acerra","year":"2014","journal-title":"Protein Sci."},{"key":"10.1016\/j.jmb.2020.11.005_b0125","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/bi5001257","article-title":"Retro-inversal of intracellular selected beta-amyloid-interacting peptides: implications for a novel Alzheimer's disease treatment","volume":"53","author":"Acerra","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2020.11.005_b0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng0298-106","article-title":"Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease","volume":"18","author":"Kruger","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.jmb.2020.11.005_b0135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/ana.10795","article-title":"The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia","volume":"55","author":"Zarranz","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jmb.2020.11.005_b0140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/mds.25421","article-title":"Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease","volume":"28","author":"Appel-Cresswell","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jmb.2020.11.005_b0145","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jmb.2020.11.005_b0150","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neurobiolaging.2014.03.024","article-title":"A novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology","volume":"35","author":"Pasanen","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jmb.2020.11.005_b0155","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/ana.23894","article-title":"G51D alpha-Synuclein mutation causes a novel Parkinsonian-pyramidal syndrome","volume":"73","author":"Lesage","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jmb.2020.11.005_b0160","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s12551-017-0353-8","article-title":"Recent progress on understanding the mechanisms of amyloid nucleation","volume":"10","author":"Chatani","year":"2018","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.jmb.2020.11.005_b0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/ijms18030478","article-title":"High-throughput screening methodology to identify alpha-synuclein aggregation inhibitors","volume":"18","author":"Pujols","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2020.11.005_b0170","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nsmb.2971","article-title":"A molecular chaperone breaks the catalytic cycle that generates toxic A beta oligomers","volume":"22","author":"Cohen","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2020.11.005_b0175","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3233\/JPD-171103","article-title":"The role of lipids interacting with alpha-synuclein in the pathogenesis of Parkinson's disease","volume":"7","author":"Galvagnion","year":"2017","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.jmb.2020.11.005_b0180","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41531-019-0095-3","article-title":"Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room","volume":"5","author":"Killinger","year":"2019","journal-title":"npj Parkinsons Dis."},{"key":"10.1016\/j.jmb.2020.11.005_b0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41531-019-0103-7","article-title":"Parkinson's disease: proteinopathy or lipidopathy?","volume":"6","author":"Fanning","year":"2020","journal-title":"npj Parkinsons Dis."},{"key":"10.1016\/j.jmb.2020.11.005_b0190","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1529\/biophysj.107.127464","article-title":"Concentration dependence of alpha-synuclein fibril length assessed by quantitative atomic force microscopy and statistical-mechanical theory","volume":"95","author":"van Raaij","year":"2008","journal-title":"Biophys. J ."},{"key":"10.1016\/j.jmb.2020.11.005_b0195","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.baga.2016.02.001","article-title":"Striatal dopamine neurotransmission: regulation of release and uptake","volume":"6","author":"Sulzer","year":"2016","journal-title":"Basal Ganglia"},{"key":"10.1016\/j.jmb.2020.11.005_b0200","doi-asserted-by":"crossref","first-page":"7872","DOI":"10.1021\/acs.jpclett.9b03005","article-title":"Lipid dynamics and phase transition within alpha-synuclein amyloid fibrils","author":"Galvagnion","year":"2019","journal-title":"J. Phys. Chem. Lett."},{"key":"10.1016\/j.jmb.2020.11.005_b0205","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41531-020-00122-1","article-title":"A series of helical alpha-synuclein fibril polymorphs are populated in the presence of lipid vesicles","volume":"6","author":"Meade","year":"2020","journal-title":"npj Parkinsons Dis."},{"key":"10.1016\/j.jmb.2020.11.005_b0210","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nsmb.3194","article-title":"Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein","volume":"23","author":"Tuttle","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2020.11.005_b0215","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/s41422-018-0075-x","article-title":"Amyloid fibril structure of alpha-synuclein determined by cryoelectron microscopy","volume":"28","author":"Li","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.jmb.2020.11.005_b0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/srep38510","article-title":"Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model","volume":"6","author":"Yedlapudi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jmb.2020.11.005_b0225","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41467-018-04422-2","article-title":"alpha-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson's disease","volume":"9","author":"Ludtmann","year":"2018","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2020.11.005_b0230","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jmb.2006.12.044","article-title":"Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity","volume":"366","author":"Volles","year":"2007","journal-title":"J. Mol. Biol."}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283620306240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283620306240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:39:21Z","timestamp":1758317961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283620306240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":46,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0022283620306240"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2020.11.005","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Library Derived 4554W Peptide Inhibits Primary Nucleation of \u03b1-Synuclein","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2020.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"166706"}}